Ash Stevens Inc.

Riverview, MI, United States

Ash Stevens Inc.

Riverview, MI, United States
SEARCH FILTERS
Time filter
Source Type

News Article | July 10, 2017
Site: www.prnewswire.com

LONDON, July 10, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables, Solid Dosage Forms, and Liquid & Semi-solid Dosage Forms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Download the full report: https://www.reportbuyer.com/product/4707109/ Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 112 companies including many key and niche players such as: - Aenova Group - Ajinomoto Althea, Inc. - Albany Molecular Research Inc. - Alcami Corporation - Baxter International, Inc. Download the full report: https://www.reportbuyer.com/product/4707109/ I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW Pharmaceutical Contract Manufacturing - A Prelude Current & Future Market Outlook Sizing the Market West Leads in PCM Services Solid Dosage Remains Popular Among CMOs Injectable-Dose Formulations to Spearhead Growth of the PCM Market Opportunities Rife for PCM Growth Key Market Drivers Major Changes Imperative to Capitalize on Brighter Future Prospects 2. MARKET TRENDS & DRIVERS Changing Face of the CMO Industry Relevance of CMOs Increases in the Modern Pharma Industry Patent Expiries Augur Good Tidings for the PCM Market PCMs Gear Up to Tap Booming Biologics Market Biotechnology Start-Ups Spur Demand for Contract Manufacturing Service Differentiation - The Key to Future Success in Solid Dosage Formulations Manufacturing Strong Growth in Injectables Market to Resonate in Contract Manufacturing Developed Markets Dominate Sterile Injectables Contract Manufacturing Market PCM Market for Vaccines Yet to Take Off PCM Industry Gravitates Eastward, and Subsequently Leads to Near-Shoring Smaller Production Batches are Here to Stay; Compel Facility Efficiency Improvements Upstream Movement Becomes a Compulsion for Many Need to Focus on Better Customer Services Emerges Rising Drug Complexity Presses for Specialized Expertise Adoption of Cutting-Edge Technologies to Radicalize PCM Environment RABS technology Quality by Design Track & Trace Techniques Disposable Processing Techniques Upstream & Downstream Processes Process Analytical Technology Near Infrared Spectroscopy Perfusion Technology Takes Center-stage as Quality and Cost Concerns Rise Downstream Processes Get a Lift as CMOs Seek Ways to Improve Capacity Biopharma Contract Manufacturing Surges Ahead Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production Contract Manufacturing of ADCs Continues to Rise Competition to Surge in Biological Contract Manufacturing Market CMOs Gear Up for Capacity Expansions to Address Growing Demand from Biopharma Ballooning Global Population Offers Increased Growth Opportunities Table 1: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart) Aging Population Boosts Opportunities for PCM Table 2: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart) Table 3: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart) Table 4: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart) Increasing Healthcare Expenditure to Spur Demand for Contract Manufacturing of Generics Table 5: Healthcare Spending as a Percentage of GDP by Region (2016E) (includes corresponding Graph/Chart) Table 6: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart) Surge in Generic Drugs to Benefit Pharmaceutical Contract Manufacturers Table 7: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart) Insourcing of Manufacturing Operations - An Emerging Threat to PCM Vendor Switching- A Growing Concern for PCMs New Challenges Threaten Prospects for CMOs New Distribution Regulations Incites Changes in Operations 3. COMPETITIVE LANDSCAPE PCM - A Highly Fragmented Industry Undergoing Consolidation Table 8: Leading Players in the Global Finished Dose Pharmaceutical Contract Manufacturing Market (2015): Percentage Breakdown of Revenues for Aenova, Baxter, Catalent, Famar, Fareva, LTS Lohmann, Nipro, Patheon/DPx, Pfizer/Hospira, Vetter and Others (includes corresponding Graph/Chart) Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart) PCMs Battle Fierce Competition and Commoditization Consolidation Wave Hits the Market Select Key CMO Mergers and Acquisitions: 2014-2016 Changing Focus on M&A Activity Investments Rise as CMOs Respond to Changing Market Needs Capacity Expansions Become Popular Options for Building Integrated Service Offerings Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service Offerings Increased Regulator Scrutiny: A Cause of Concern for the Emerging Market PCMs 4. SERVICE OVERVIEW Introduction Injectables (Injections, Vials, and IV solutions) Solid Dosage Forms (SDFs) (Tablets and Capsules) Liquid Dosage Forms (LDFs) (Syrups and Suspensions) An Insight into the Rise of Pharmaceutical Contract Manufacturing Investment Risks in Pharmaceutical Contract Manufacturing Quality Assurance Risk Drug Development Risk Acquisition Risk Client Dependency Risk 5. RECENT INDUSTRY ACTIVITY KDPharma to Merge with Marine Ingredients Suanfarma Acquires Stake in Idifarma Recipharm Inks Long-Term Commercial Manufacturing Contract with Tillots Propanc Inks Contract Manufacturing Deal with AmatsiQBiologicals BioTechnique Commences Vaccine Manufacturing under Partnership with NPO Piramal Pharma Solutions Acquires Ash Stevens Saneca Sells Registration Dossiers for 20 Products to Xantis, Retains Manufacturing Rights Evonik Takes Over Transferra Famar to Acquire Roche's Leganes Site Mylan Acquires Part Business of Renaissance Averica and Dalton Pharma Ink Preferred Provider Agreement AGC Asahi Glass Takes Over Biomeva BioDuro and Formex Merge Frontida Acquires Sun Pharma's US Manufacturing Facilities Recipharm Inks Agreement to Take Over CDMO from Kemwell Generic Specialties Takes Over Axcellerate Pharma Pfizer Establishes Pfizer CentreOne Specialty CMO Caisson Biotech Inks Manufacturing Agreement with CordenPharma Brammer and Florida Biologix Merge AAIPharma and Cambridge Major Laboratories Merge to form Alcami Recipharm to Acquire Mitim TxCell Signs CMO Deal with MaSTherCell Boehringer Ingelheim to Commence First Biopharma CMO Pilot Project in China Enteris Commences Contract Manufacturing Service at its Facility Capsugel Takes Over Powdersize and Xcelience Synerlab Acquires Alcala Farma Recipharm Inks Deal to Take Over Majority Stake in Nitin Lifesciences Pfizer Acquires Hospira Avista Pharma Takes Over Scynexis CMO and Animal Health Businesses Lonza and Nikon Team Up for New Contract Manufacturing Facility Piramal Acquires Coldstream SK Capital Takes Over Halo Pharmaceutical FUJIFILM Acquires Kalon Biotherapeutics Bayer Selects Cardinal Health as Contract Manufacturer for Xofigo® Recipharm Takes Over Manufacturing Facility and Contracts from Flamel Baring to Acquire Bushu Pharmaceuticals Recipharm Takes Over Lusomedicameta Strides Arcolab and Shasun to Merge Kinex Pharmaceuticals Acquires QuaDPharma Patheon Acquires Gallus BioPharmaceuticals Packaging Coordinators Takes Over Penn Pharma Sun Pharmaceutical Takes Over Pharmalucence AMRI Acquires Oso Biopharmaceuticals Manufacturing Carlyle Group Takes Over Sunsho Pharmaceutical AMRI Acquires Cedarburg Par Pharmaceutical to Take Over JHP JLL Partners and Royal DSM Merger Businesses to form DPx Meiji Holdings Buys Medreich Lifecare Limited Emilia Group Takes Over Pharma Pac LLC Emergent BioSolutions Takes Over Cangene Corporation 6. FOCUS ON SELECT PLAYERS Aenova Group (Germany) Ajinomoto Althea, Inc. (US) Albany Molecular Research Inc. (US) Alcami Corporation (US) Baxter International, Inc. (US) Boehringer Ingelheim GmbH (Germany) Catalent Pharma Solutions, Inc. (US) Cobra Biologics Holding AB (Sweden) CordenPharma International (Germany) Dishman Group (India) DPx Holdings B.V. (US) Fareva Group (Luxembourg) Famar Health Care Services (Greece) Hospira, Inc. (US) Jubilant Life Sciences Limited (India) Kemwell Biopharma Pvt. Ltd. (India) Lonza Group Ltd. (Switzerland) LTS Lohmann Therapie-Systeme AG (Germany) NextPharma Technologies Holding Ltd. (UK) Nipro Pharma Corporation (Japan) Recipharm AB (Sweden) Vetter Pharma International GmbH (Germany) 7. GLOBAL MARKET PERSPECTIVE Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 11: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 12: World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) Table 13: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 14: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 15: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) Table 16: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 17: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 18: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) Table 19: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 20: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 21: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III. MARKET 1. THE UNITED STATES A.Market Analysis US PCM Market Overview Domestic Contract Manufacturing Market Sees New Vigor Competitive Landscape Strategic Corporate Developments Select Key Players B.Market Analytics Table 22: The US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 23: The US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 24: The US 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 2. CANADA A.Market Analysis Current & Future Analysis Strategic Corporate Developments B.Market Analytics Table 25: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 26: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 27: Canadian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 3. JAPAN A.Market Analysis Current & Future Analysis Strategic Corporate Developments Nipro Pharma Corporation - A Key Japanese Player B.Market Analytics Table 28: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 29: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 30: Japanese 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 4. EUROPE A.Market Analysis Market Overview Injectables Segment Offers Promising Potential Mammalian Cell Technology Dominates PCM Market Competitive Scenario Overview of Select Markets Germany Russia B.Market Analytics Table 31: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 32: European Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 33: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain and Rest of European Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) Table 34: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 35: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 36: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 4a. FRANCE A.Market Analysis Current & Future Analysis Strategic Corporate Development B.Market Analytics Table 37: French Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 38: French Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 39: French 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 4b. GERMANY A.Market Analysis Current & Future Analysis Strategic Corporate Developments Key Players B.Market Analytics Table 40: German Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 41: German Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 42: German 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 4c. ITALY A.Market Analysis Current & Future Analysis Strategic Corporate Development B.Market Analytics Table 43: Italian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 44: Italian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 45: Italian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 4d. THE UNITED KINGDOM A.Market Analysis Current & Future Analysis Strategic Corporate Development Key Player B.Market Analytics Table 46: UK Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 47: UK Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 48: UK 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 4e. SPAIN A.Market Analysis Current & Future Analysis Strategic Corporate Developments B.Market Analytics Table 49: Spanish Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 50: Spanish Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 51: Spanish 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 4f. REST OF EUROPE A.Market Analysis Current & Future Analysis Strategic Corporate Developments Key Players B.Market Analytics Table 52: Rest of European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 53: Rest of European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 54: Rest of European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 5. ASIA-PACIFIC A.Market Analysis Favorable Government Policies Transform China and India into PCM Hubs Competitive Scenario Overview of Select Key Markets India India - A Stronghold for Pharmaceutical Contract Manufacturing Market Sees Transitory Turbulence Indian PCMs Battle Soaring Costs Outlook Remains Promising China China Presents Enormous Opportunities for Contract Manufacturing Strategic Corporate Developments Select Key Players B.Market Analytics Table 55: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 56: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 57: Asia-Pacific 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) 6. REST OF WORLD Market Analysis Table 58: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart) Table 59: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart) Table 60: Rest of World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 112 (including Divisions/Subsidiaries - 125) The United States (54) Canada (2) Japan (7) Europe (40) - France (6) - Germany (10) - The United Kingdom (7) - Italy (3) - Spain (2) - Rest of Europe (12) Asia-Pacific (Excluding Japan) (21) Middle East (1) Download the full report: https://www.reportbuyer.com/product/4707109/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com


Negmeldin A.T.,Wayne State University | Padige G.,Wayne State University | Bieliauskas A.V.,Wayne State University | Bieliauskas A.V.,Ash Stevens Inc. | Pflum M.K.H.,Wayne State University
ACS Medicinal Chemistry Letters | Year: 2017

Histone deacetylase (HDAC) proteins are epigenetic regulators that deacetylate protein substrates, leading to subsequent changes in cell function. HDAC proteins are implicated in cancers, and several HDAC inhibitors have been approved by the FDA as anticancer drugs, including SAHA (suberoylanilide hydroxamic acid; Vorinostat and Zolinza). Unfortunately, SAHA inhibits most HDAC isoforms, which limits its use as a pharmacological tool and may lead to side effects in the clinic. In this work SAHA analogues substituted at the C2 position were synthesized and screened for HDAC isoform selectivity in vitro and in cells. The most potent and selective compound, C2-n-hexyl SAHA, displayed submicromolar potency with 49- to 300-fold selectivity for HDAC6 and HDAC8 compared to HDAC1, -2, and -3. Docking studies provided a structural rationale for selectivity. Modification of the nonselective inhibitor SAHA generated HDAC6/HDAC8 dual selective inhibitors, which can be useful lead compounds toward developing pharmacological tools and more effective anticancer drugs. © 2017 American Chemical Society.


Bieliauskas A.V.,Wayne State University | Bieliauskas A.V.,Ash Stevens Inc. | Weerasinghe S.V.W.,Wayne State University | Weerasinghe S.V.W.,University of Michigan | And 2 more authors.
Archiv der Pharmazie | Year: 2016

Histone deacetylase (HDAC) proteins have emerged as targets for anti-cancer therapeutics, with several inhibitors used in the clinic, including suberoylanilide hydroxamic acid (SAHA, vorinostat). Because SAHA and many other inhibitors target all or most of the 11 human HDAC proteins, the creation of selective inhibitors has been studied intensely. Recently, inhibitors selective for HDAC1 and HDAC2 were reported where selectivity was attributed to interactions between substituents on the metal binding moiety of the inhibitor and residues in the 14-Å internal cavity of the HDAC enzyme structure. Based on this earlier work, we synthesized and tested SAHA analogs with substituents on the hydroxamic acid metal binding moiety. The N-substituted SAHA analogs displayed reduced potency and solubility, but greater selectivity, compared to SAHA. Docking studies suggested that the N-substituent accesses the 14-Å internal cavity to impart preferential inhibition of HDAC1. These studies with N-substituted SAHA analogs are consistent with the strategy exploiting the 14-Å internal cavity of HDAC proteins to create HDAC1/2 selective inhibitors. © 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.


Ammoscato V.,Ash Stevens Inc. | Wickenheiser R.,Ash Stevens Inc. | Henderson J.,Ash Stevens Inc. | Munk S.,Ash Stevens Inc.
Drug Development Research | Year: 2010

Most cancer drugs are quite potent and represent a potential hazard to chemists conducting their synthesis. Chemical development teams must therefore integrate proper handing techniques for such compounds into their development plans. We describe the synthesis of the drug busulfan using barrier isolation technology. These systems are a general solution for the safe handling of many potent drugs, including those used to treat cancer. © 2010 Wiley-Liss, Inc.


Goddard S.,Ash Stevens Inc.
Process Safety Progress | Year: 2012

Herein, we present the steps a small pharmaceutical research and development company is taking to prepare for process safety management (PSM). Although not regulated by PSM at the present time, the corporate growth plan is such that PSM will be a requirement within the next 2-5 years. When looking at the safety management systems in use by many major companies, safety personnel at small companies can become overwhelmed by the daunting task before them. Preparation is key for a small company that must use available resources efficiently in order to accomplish day to day activities. © 2012 American Institute of Chemical Engineers (AIChE).


Cohen D.,Amgen Inc. | Cosbie A.,Amgen Inc. | Milburn R.R.,Amgen Inc. | Shaw S.,Amgen Inc. | And 2 more authors.
Organic Process Research and Development | Year: 2014

The safe implementation of a hydrogen-peroxide-mediated oxidation of a poorly reactive sulfide to the corresponding sulfone is described. A three-tiered approach incorporating process understanding, safety studies, and real time PAT (in situ Raman spectroscopy) was leveraged to ensure safe operation. Further investigation of an in situ Raman spectroscopy model for the reaction and its use for in-process control and end-point determination is discussed. © 2014 American Chemical Society.


Kiser E.J.,Ash Stevens Inc. | Magano J.,Pfizer | Shine R.J.,Pfizer | Chen M.H.,Wuhan Institute of Technology
Organic Process Research and Development | Year: 2012

A scalable method for the preparation of oxindole 8, a key intermediate en route to a serine palmitoyl transferase inhibitor, compound 1, is presented. A three-step, chromatography-free route has been designed that takes advantage of Buchwald's palladium-catalyzed C-H functionalization to cyclize an α-chloroacetanilide to form the five-membered ring. This process has been successfully carried out in our kilogram laboratory facility on 10-kg scale in 76% yield. © 2011 American Chemical Society.


Roberts S.W.,Amgen | Shaw S.M.,Amgen | Shaw S.M.,Ash Stevens Inc. | Milne J.E.,Amgen | And 4 more authors.
Organic Process Research and Development | Year: 2012

The Ritter reaction utilizing tert-butyl acetate as the tert-butyl cation source was investigated by in situ FTIR and calorimetry under various reaction conditions. It was established that, when a batch mode reaction in acetic acid was performed, minimal isobutylene was evolved into the headspace, thereby avoiding pressurization of the reaction vessel. The safety of these conditions is due to the equilibrium of isobutylene and acetic acid with tert-butyl acetate. In addition, the observation of acetic anhydride provided insight into the role of acetic acid in the mechanistic pathway. © 2012 American Chemical Society.


Goddard S.,Ash Stevens Inc.
Global Congress on Process Safety 2012 - Topical Conference at the 2012 AIChE Spring Meeting and 8th Global Congress on Process Safety | Year: 2012

Herein we present the steps a small pharmaceutical research and development company is taking to prepare for Process Safety Management (PSM). Although not regulated by PSM at the present time, the corporate growth plan is such that PSM will be a requirement within the next 2 to 5 years. When looking at the safety management systems in use by many major companies, safety personnel at small companies can become overwhelmed by the daunting task before them. Preparation is key for a small company that must use available resources efficiently in order to accomplish day to day activities. © 2012 Ash Stevens Inc.


Patent
Pharmion and Ash Stevens Inc. | Date: 2010-05-05

The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms. The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.

Loading Ash Stevens Inc. collaborators
Loading Ash Stevens Inc. collaborators